Roy Maute

June 12, 2023

Roy is a scientist and biotechnology entrepreneur, and is a co-founder of Pheast Therapeutics. He serves as the company’s Chief Executive Officer and leads Pheast’s Research and Development teams. Prior to Pheast, he led the biomarker and translational science for the clinical anti-CD47 and anti-SIRPA programs at Forty Seven Inc. and Gilead Sciences. Roy also co-founded Ab Initio Biotherapeutics, an antibody discovery company acquired by Ligand Pharmaceuticals in 2019. He trained as a postdoctoral fellow in the laboratory of Dr. Irving Weissman at Stanford University School of Medicine. Roy received his Ph.D. in genetics from Columbia University and a B.A. in molecular and cell biology from UC Berkeley.